KRN5500 granted orphan drug designation for the treatment of myeloma

DARA Biosciences Inc., an American pharmaceutical company, has announced that the FDA has granted Orphan Drug Designation for its investigational drug KRN5500 for the treatment of myeloma. KRN5500 is a novel, intravenous, non-opioid, non-narcotic compound currently being developed for the parenteral treatment of painful, chronic, chemotherapy-induced peripheral neuropathy. Pre-clinical studies show that KRN5500, a spicimycin…

Details